MediciNova's Ibudilast And The Phase IIb Trial Offer Steady Outlook
I/we have no positions in any stocks mentioned, but may initiate a long position in MNOV over the next 72 hours. I wrote this article myself, and it expresses my own opinions.
from Biotech News
0 Comments